Hypoxia targeting lutetium-177-labeled nitroimidazole-decorated gold particles as cancer theranostic nanoplatforms

Gold nanoparticles as cancer theranostic agents

The application of nanotechnology in medicine involves using nanomaterials to develop novel therapeutic and diagnostic modalities. Given the unique physiochemical and optical properties of gold nanoparticle (GNP) such as good biocompatibility, nontoxic nature, surface properties and comparative stability, it has been widely studied in medicine, especially as a cancer theranostic agent. Th...

Preparation and Evaluation of Lu Labeled Nitroimidazole Derivative for Targeting Tumor Hypoxia

Hypoxia has been known be an important physiological parameter for tumor growth and has been reported to be the cause for poor response to chemotherapy. Mechanistically, tumor hypoxia results from an imbalance between oxygen delivery and oxygen consumption. The identification and quantification of tumor hypoxia may predict the out come and may identify patients who might benefit from concomitan...

Lu-177-Labeled Zirconia Particles for Radiation Synovectomy.

The present article describes the preparation of β-emitter lutetium-177-labeled zirconia colloid and its preliminary physicochemical and biological evaluation of suitability for local radionuclide therapy. The new (177)Lu-labeled therapeutic radiopharmaceutical candidate was based on the synthesis mode of a previously described zirconia nanoparticle system. The size and shape of the developed r...

Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System

OBJECTIVES Peptide Receptor Radionuclide Therapy (PRRT) with yttrium-90 ((90)Y) and lutetium-177 ((177)Lu)-labelled SST analogues are now therapy option for patients who have failed to respond to conventional medical therapy. In-house production with automated PRRT synthesis systems have clear advantages over manual methods resulting in increasing use in hospital-based radiopharmacies. We repor...

Production and Evaluation of Lutetium-177 Maltolate as a Possible Therapeutic Agent